Adjuvant drug treatment for resectable breast cancer

Oncologist

Volumn 2, Issue 6, 1997, Pages 351-358

  Hudis, Clifford A ^a   Norton, Larry ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Adjuvant therapy; Breast cancer; Chemotherapy; Clinical trials; Hormone therapy

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ESTRADIOL; ESTROGEN RECEPTOR; FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR; METHOTREXATE; PACLITAXEL; TAMOXIFEN;

ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS;

EID: 0031460501     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.2-6-351     Document Type: Article

References (11)

1. Parker S, Tong T, Bolden S et al. Cancer statistics, 1997. CA-A Cancer Journal For Clinicians 1997;47:5-27.
2. Halsted WS. The results of operations for the cure of cancer of the breast performed at the Johns Hopkins Hospital from June 1889 to January 1894. Johns Hopkins Hosp Rep 1894;4:297-350.
3. Halsted WS. The results of radical operations for the cure of carcinoma of the breast. Ann Surg 1907;46:1-19.
4. Fisher B. The evolution of paradigms for the management of breast cancer: a personal perspective. Cancer Res 1992;52:2371-2383.
5. Beatson GT. On the treatment of inoperable carcinoma of the mamma: suggestions for a new method of treatment, with illustrative cases. Lancet 1896;ii:104-107.
6. Paterson R, Russell M. Clinical trials in malignant disease. Part II. Breast cancer: value of irradiation of the ovaries. J Faculty Radiologists 1959;10:130-133.
7. Early Breast Cancer Trialists Group. Ovarian ablation in early breast cancer: overview of the randomized trials. Lancet 1996;348:1189-1196.
8. Early Breast Cancer Trialists Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 1992;339:1-15, 71-85.
9. Gelber RD, Goldhirsch A. Reporting and interpreting adjuvant therapy clinical trials. J Natl Cancer Inst (Monograph) 1992:11:59-69.
10. Gelber RD, Goldhirsch A, Coates AS. Adjuvant therapy for breast cancer: understanding the overview. J Clin Oncol 1993;11:580-585.
11. Hudis C, Norton L. Adjuvant drug therapy for operable breast cancer. Semin Oncol 1996;23:475-493.